Journal Title
Title of Journal: Curr Treat Options Cardio Med
|
Abbravation: Current Treatment Options in Cardiovascular Medicine
|
Publisher
Current Science Inc.
|
|
|
|
|
|
Authors: Charles V Pollack
Publish Date: 2012/10/20
Volume: 15, Issue: 1, Pages: 21-32
Abstract
Anticoagulation with a parenteral intravenous or subcutaneous antithrombin agent is foundational to the early management of acute coronary syndrome ACS While indications for the timing of and the choice among agents other than aspirin that provide antiplatelet effects are all subject to discussion the need for acute anticoagulation is beyond question There are a number of agents that can be used for anticoagulation in ACS depending upon the intended nearterm management of the patient medical vs interventional the patient’s ischemic risk and the patient’s hemorrhagic risk It is usually appropriate for therapy to be initiated in the emergency department ED which in turn supports close collaboration between “upstream” providers and interventional cardiologists Clinical trial data suggest that “switching” agents during ACS care affords no efficacy advantage and may increase bleeding risk At least 1 potential new agent otamixaban that can be used in all ACS care settings is on the nearterm horizon with the drug currently in late Phase III testing
Keywords:
.
|
Other Papers In This Journal:
|